Cargando…

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver diseases worldwide and can develop into various conditions, ranging from simple steatosis, through non-alcoholic steatohepatitis (NASH), to fibrosis, and eventually cirrhosis and hepatocellular carcinoma. Nevertheles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Lili, Hong, Wei, Lu, Shen, Li, Yanrong, Guan, Yaya, Weng, Xiaogang, Feng, Zhiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957978/ https://www.ncbi.nlm.nih.gov/pubmed/35350750 http://dx.doi.org/10.3389/fphar.2022.780496

Ejemplares similares

Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
por: Torres, Sandra, et al.
Publicado: (2022)

Pharmacological effects of Chinese medicine modulating NLRP3 inflammasomes in fatty liver treatment
por: Liu, Tingting, et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in Lupus Nephritis and Therapeutic Targeting by Phytochemicals
por: Wu, Dantong, et al.
Publicado: (2021)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

CBD Alleviates Liver Injuries in Alcoholics With High-Fat High-Cholesterol Diet Through Regulating NLRP3 Inflammasome–Pyroptosis Pathway
por: Jiang, Xuye, et al.
Publicado: (2021)

Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome
por: Yang, Gabsik, et al.
Publicado: (2020)

Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
por: Ding, Nan, et al.
Publicado: (2020)

Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease
por: Xu, Jingqi, et al.
Publicado: (2021)

Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022)

Neurodegenerative Disease and the NLRP3 Inflammasome
por: Holbrook, Jonathan A., et al.
Publicado: (2021)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
por: Blas-García, Ana, et al.
Publicado: (2022)

NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ
por: Chen, Yu, et al.
Publicado: (2018)

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design
por: Wang, Xinxue, et al.
Publicado: (2023)

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

Natural Products as a Novel Therapeutic Strategy for NLRP3 Inflammasome-Mediated Gout
por: Lee, Jun Ho, et al.
Publicado: (2022)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Wu, Jingyi, et al.
Publicado: (2023)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

The role of NLRP3 inflammasome in hepatocellular carcinoma
por: Zhao, Huijie, et al.
Publicado: (2023)

Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update
por: Yu, Qingying, et al.
Publicado: (2021)

Role of the inflammasome in insulin resistance and type 2 diabetes mellitus
por: Lu, Shen, et al.
Publicado: (2023)

Erratum: Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Frontiers Production Office,
Publicado: (2023)

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome
por: Zhang, Huicun, et al.
Publicado: (2022)

NLRP3 inflammasome and its inhibitors: a review
por: Shao, Bo-Zong, et al.
Publicado: (2015)

Activation of Platelet NLRP3 Inflammasome in Crohn’s Disease
por: Zhang, Ge, et al.
Publicado: (2021)

C646 Protects Against DSS-Induced Colitis Model by Targeting NLRP3 Inflammasome
por: Xu, Xueming, et al.
Publicado: (2021)

A novel strategy for bioactive natural products targeting NLRP3 inflammasome in Alzheimer’s disease
por: Yang, Zhiyou, et al.
Publicado: (2023)

Natural flavonoids: Potential therapeutic strategies for non-alcoholic fatty liver disease
por: Tan, Panli, et al.
Publicado: (2022)

The NLRP3 inflammasome is involved in resident intruder paradigm-induced aggressive behaviors in mice
por: Yu, Qingying, et al.
Publicado: (2023)

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
por: Xu, Xiaohan, et al.
Publicado: (2022)

MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies
por: Tezcan, Gulcin, et al.
Publicado: (2019)

Pharmacological intervention of curcumin via the NLRP3 inflammasome in ischemic stroke
por: Du, Xiaoxue, et al.
Publicado: (2023)

Lipophagy and Alcohol-Induced Fatty Liver
por: Yang, Li, et al.
Publicado: (2019)

Yupingfeng San Inhibits NLRP3 Inflammasome to Attenuate the Inflammatory Response in Asthma Mice
por: Liu, Xue, et al.
Publicado: (2017)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol
por: Hartmann, Alice, et al.
Publicado: (2023)

Teuvincenone F Suppresses LPS-Induced Inflammation and NLRP3 Inflammasome Activation by Attenuating NEMO Ubiquitination
por: Zhao, Xibao, et al.
Publicado: (2017)

Amentoflavone Affects Epileptogenesis and Exerts Neuroprotective Effects by Inhibiting NLRP3 Inflammasome
por: Rong, Shikuo, et al.
Publicado: (2019)

Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD
por: Huang, Qian, et al.
Publicado: (2022)

Saikosaponin d Alleviates Liver Fibrosis by Negatively Regulating the ROS/NLRP3 Inflammasome Through Activating the ERβ Pathway
por: Zhang, Kehui, et al.
Publicado: (2022)

Platelets in Non-alcoholic Fatty Liver Disease
por: Dalbeni, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_23u01fiivfv8odc20tsiubd6ei